BioPharma DiveOriginal article
FDA extends review of Capricor cell therapy; Pain drug startup to go public
RegulatoryderamiocelNeutral
AI Analysis
Summary
FDA has extended its review of Capricor's deramiocel cell therapy with a refined indication. Additionally, a pain drug startup co-founded by Vivek Ramaswamy is preparing for a public market listing.
Outcome Details
FDA extending review of updated application with refined indication
Importance:5/10
Sentiment:
0.00
FDA review extensioncell therapyregulatory updateIPO
Related Companies
Read the original article
Published by BioPharma Dive on August 24, 2026 3:30 PM